Siren MK, Julkunen H, Kaaja R.— The increasing incidence of isolated congenital heart block in Finland. J Rheumatol, 1998, 25, 1862-1864.
Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al.— Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum, 2004, 50, 3187-3194.
Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al.— Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/ Ro associated cardiac manifestations of neonatal lupus. Circulation, 2012, 126, 76-82.
Buyon JP, Hiebert R, Copel J, et al.— Autoimmune-associated congenital heart-block: demographics, mortality, morbidity, and recurrences rates obtained from a national neonatal lupus registry. JACC, 1998, 31, 1658-1666.
Eliasson H, Sonesson SE, Sharland G, et al.— Isolated atrioventricular block in the fetus: a retrospective multinational, multicenter study of 175 patientes. Circulation, 2011, 124, 1919-1926.
Monsarrat N, Houfflin-Debarge V, Richard A, et al.— Echographie et Doppler fœtaux dans le bloc auriculoventriculaire congénital d’origine immunologique. Gynecol Obstet Fertil, 2009, 37, 633-644.
Groves AM, Allan LD, Rosenthal E.— Outcome of isolated congenital complete heart block diagnosed in utero. Heart, 1996, 75, 190-194.
Berg C, Geipel A, Kohl T, et al.— Atrioventricular block detected in fetal life: associated anomalies and potential pronostic makers. Ultrasound Obstet Gynecol, 2005, 26, 4-15.
Clancy RM, Neufing PJ, Zheng P, et al.— Impaired clearance of apoptotic cardiocytes in linked to anti-SSA/Ro and –SSB/ La antibodies in the pathogenesis of congenital heart block. J Clin Invest, 2006, 116, 2413-2422.
Salomonsson S, Sonesson SE, Ottosson L, et al.—Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med, 2005, 201, 11-17.
Alvarez D, Briassouli P, Clancy RM, et al.— A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem, 2011, 286, 30444-30454.
Morel N, Georgin-Lavialle S, Levesque K, et al.— « Lupus néonatal»: revue de la littérature. Rev Med Int, 2015, 36, 159-166.
Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, et al.— Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis, 2003, 62, 1010-1012.
Spinillo A, Viazzo F, Colleoni R, et al.— Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol, 2004, 191, 217-224.
Saxena A, Izmirly PM, Mendez B, et al.— Prevention and treatment in utero of autoimmune associated congenital heart block. Cardiol Rev, 2014, 22, 263-267.
Robinson BV, Ettedgui JA, Sherman FS.— Use of terbutaline in the treatment of complete heart block in the fetus. Cardiol Young, 2001, 11, 683-686.
Groves AM, Allan LD, Rosenthal E.— Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation, 1995, 92, 3394-3396.
Pisoni CN, Brucato A, Ruffatti A, et al.— Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum, 2010, 62, 1147-1152.
Martinez-Sanchez N, Perez-Pinto S, Robles-Marhuenda A, et al.— Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study. Immunol Res, 2017, 65, 487-494.
Flint J, Panchal S, Hurrel A, et al.— BSR and BHPR Standards Guidelines and Audit Working Group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford), 2016, 55, 1693-1697.